B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL)

Monica Balzarotti, Ercole Brusamolino, E. Angelucci, Angelo Michele Carella, U. Vitolo, Eleonora Russo, Angelagiovanna Congiu, Manuel Gotti, Stefania Massidda, B. Botto, Giorgia Annechini, Michele Spina, Alessandro Re, Vittorio Ruggero Zilioli, Francesco Merli, Flavia Salvi, Caterina Stelitano, Maurizio Bonfichi, Marcello Rodari, Roberta MurruMassimo Magagnoli, Antonella Anastasia, Rita Mazza, Laura Giordano, Armando Santoro

Research output: Contribution to journalArticle


This randomized, multicenter study evaluates the addition of bortezomib (13 mg/m2) to IGEV (B-IGEV) in patients with relapsed/refractory Hodgkin Lymphoma (HL). Patients received either four courses of IGEV alone (n = 40) or B-IGEV (n = 40). The primary endpoint was the complete response (CR) proportion, evaluated by FDG-PET, after induction chemotherapy. CR proportion was 39% with B-IGEV and 53% with IGEV. PFS and OS were similar between the two groups (two-year PFS: 58% vs 56%; two-year OS: 93% vs 81%). The PET-negative status after treatment was the only variable favorably influencing both PFS (two-year PFS: 77% vs 40%; p = 0.002) and OS (two-year OS: 100% vs 76%; p 

Original languageEnglish
Pages (from-to)2375-2381
Number of pages7
JournalLeukemia and Lymphoma
Publication statusAccepted/In press - Feb 12 2016



  • Chemotherapeutic approaches
  • clinical results
  • lymphoma and Hodgkin lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this